Search PubMed⌕ Search

Biomedical subjects

K Shida

Publications and source records attributed to K Shida.

At least 19 recordsLinked to original sources
PubMed1992

Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases.

Metastatic frequency to various organ sites in 137 autopsy cases with histologically confirmed prostatic adenocarcinoma was examined retrospectively. Bone lymph node metastases were observed in 81% and 82.5% of the cases, respectively. Lung and liver metastases were noted in 46.7% and 30.7% of the cases respectively. Statistical analysis of the inter-relation among metastases to the bones, lymph nodes, lungs and liver revealed that 83.2% of cases with lymph node metastasis also had bone metastasis. Sixty out of 64 cases with lung metastasis also presented with bone metastasis. There was a significant correlation of metastases between bones and lymph nodes, bones and lungs, and lymph nodes and lungs. Although approximately 88% of cases with liver metastasis also had bone metastasis, this relationship was not statistically significant. there was a statistically significant relationship between lung metastasis and specific sites of bone metastases, i.e. vertebrae, ribs, and sternum. Using the Cochran-Mantel-Haenszel statistical method, we found that the metastatic combination between lung and bone was significantly related in cases with or without lymph node metastasis. These observations suggest that the Batson's vertebral system might play an important role in the metastatic spread of prostatic adenocarcinoma either to the bones or lungs.

Adenocarcinoma↗
PubMed1991

[Evaluation of dopamine and dobutamine for use in circulatory depression associated with induced total spinal block].

We carried out total spinal block (T.S.B.) in adult mongrel dogs with 0.5 ml.kg-1 of 2% lidocaine, and compared the effects of dopamine (DOA) and dobutamine (DOB) to correct the circulatory depression produced by T.S.B. HR, MAP, LV dp/dt max. and CI decreased significantly by T.S.B. under continuous infusion of 2.5 mcg.kg-1.min-1 of both DOA and DOB. During DOA infusion these circulatory values decreased significantly compared with those of control period, while during DOB infusion they were unchanged. MAP, LV dp/dt max. and CI decreased significantly by T.S.B. under 5 mcg.kg-1.min-1 of DOA infusion, while influence was hardly observed by T.S.B. under DOB infusion. From the results, it is concluded that DOB is more effective than DOA to correct the circulatory depression by T.S.B., and in order to correct it more than 5 mcg.kg-1.min-1 of DOA and approx. 2.5 mcg.kg-.min-1 of DOB are necessary.

Anesthesia, Spinal↗
PubMed1986

Effect of 16 beta-ethyl-17 beta-hydroxy-4-estren-3-one (TSAA-291) on the binding of promegestone (R5020) and methyltrienolone (R1881) to hyperplastic and neoplastic human prostate.

The effect of a synthetic steroidal compound TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-estren-3-one) on the binding of methyltrienolone (R1881) and promegestone (R5020) to hyperplastic and neoplastic human prostate was investigated. TSAA-291 inhibits both androgen and progestogen binding to hyperplastic and neoplastic human prostate. Glycerol density gradient analysis revealed that the inhibition of promegestone (R5020) binding by TSAA-291 was significantly greater than that of methyltrienolone (R1881) in both hyperplastic and neoplastic human prostate. The nature of the inhibition was competitive as determined by Scatchard analysis and double reciprocal plots. Comparison of the Ki values for the inhibition by TSAA-291 of R1881 binding (3.2 X 10(-7) M) and of R5020 binding (2.0 X 10(-8) M) suggests that TSAA-291 binds to progesterone receptor with a greater affinity than to androgen receptor. Our results suggest that the effectiveness of the drug in the treatment of benign hyperplasia might be due not only to its anti-androgenic properties but also due to its ability to inhibit progesterone receptor.

Binding, Competitive↗
PubMed1986

[Clinical effects of allylestrenol on benign prostatic hypertrophy by double-blind method].

A double blind comparative clinical trial was performed with allylestrenol (AE) and chlormadinone acetate (CMA) to investigate the clinical efficacy of AE on prostatic hypertrophy. Both drugs were administered orally for 12-16 weeks in a daily dose of 50 mg. With both drugs marked improvement of disorders of micturition and a slight decrease in the size of the hypertrophied prostatic node were observed. No significant difference was observed between the two drugs in the overall efficacy of the treatments. Significant improvement of practically all parameters used for evaluation of results was observed with both drugs following treatment. Ultrasonotomographic examination revealed diminution of the size of the prostatic node and x-ray examination of the ureter showed improvement in elevation of the fundus of the bladder. These improvements were better after CMA treatment than after AE treatment. With all other parameters used no significant difference was observed between the two drugs. Mild adverse effects such as loss of sexual desire and potency were observed in a few cases. The incidence of side-effects was lower following AE treatment, and the incidence of loss of sexual desire and potency was significantly lower after AE than after CMA. Taking into consideration efficacy and safety of the treatments, no significant difference was observed in usefulness between the two drugs, and we were able to confirm the usefulness of AE for the conservative treatment of prostatic hypertrophy.

Administration, Oral↗
PubMed1985

Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer.

Twenty-two patients with prostatic cancer were treated for 12 to 52 weeks with the luteinizing hormone-releasing hormone agonist, (D-Leu6)-des Gly-NH2 10-LHRH ethylamide (leuprolide). The clinical efficacy of leuprolide was evaluated at 12 weeks according to NPCP criteria. All seven patients with Stage B and C disease demonstrated a partial objective regression. The objective response rate in 12 previously untreated Stage D patients was 92% (partial regression: 5; stable disease: 6). In three relapsing Stage D patients, one demonstrated stable disease and two failed to respond to leuprolide therapy. Even though the dose of leuprolide used in this study was high, no serious side effects were observed in any patients. There was a large increase in serum FSH and LH levels during the first few days of treatment, but serum FSH and LH levels fell below the initial levels by 1 and 2 weeks, respectively. Serum testosterone fell to less than 1 ng/ml within 3 weeks, and at 12 weeks it was 7.99% of the initial level. The present study shows that chronic administration of leuprolide in high doses can safely and effectively reduce the level of serum testosterone in patients with prostatic cancer.

Adenocarcinoma↗
PubMed1979

Fabry disease: cellular expression of enzyme deficiency in nerve xenografts.

Human sural nerve fascicles from a patient with Fabry disease were transplanted into nude-mouse sciatic nerves to determine whether transplanted perineurial cells and smooth-muscle cells of an epineurial artery would express the genetic abnormality of the disease. Four months after grafting, both perineurial cells and smooth-muscle cells contained the cytoplasmic lamellated inclusion bodies characteristic of Fabry disease. This provided evidence of human perineurial cells and smooth-muscle cells in the regenerated xenografts.

Adult↗
PubMed1979

Effects of antiprostatic agents on 5alpha-dihydrotestosterone binding to rat hypophyseal and hypothalamic cytosol macromolecules.

The binding of 5alpha-dihydrotestosterone to the hypophyseal and hypothalamic cytosol macromolecules prepared from castrated male rats was observed. The effects of antiprostatic agents on 5alpha-dihydrotestosterone binding to both hypophyseal and hypothalamic cytosol macromolecules was examined. Cyproterone acetate and chlormadionone acetate showed the significant inhibiting effects on 5alpha-dihydrotestosterone binding to 7-8 S macromolecules of cytosol from both hypophysis and hypothalamus. SCH 13521 and AA 560 did also affect 5alpha-dihydrotestosterone binding to 7-8 S macromolecules of cytosol from both tissues.

Androgen Antagonists↗
PubMed1977

Effect of estracyt on the rat prostate.

Two types of experiments were performed to elucidate the estrogenic effect of estracyt on the ventral and immature rats that had received injections of testosterone; then changes in weight of accessory rats and changes in weight of the total body, the ventral and the dorsolateral prostates, and adrenal gland, and changes in activities of testosterone 5alpha-reductase, alkaline phosphatase, and arginase of both lobes of the prostates were examined. In the second experiment, estracyt was injected into castrates rats and immature rats that had received injections of testosterone; then changes in weight of accessory sex organs were determined. Because similar changes were induced by treatment of animals with estradiol-17beta, it was concluded that the effect of estracyt on the prostates was most likely attributable to the estrogenic effect of the drug.

3-Oxo-5-alpha-Steroid 4-Dehydrogenase↗